Prolonged chronic phase in chronic myelogenous leukemia after homoharringtonine therapy

Chinese Medical Journal

Volumn 122, Issue 12, 2009, Pages 1413-1417

  Li, Yu Feng ^a,b   Deng, Zhi Kui ^b   Xuan, Heng Bao ^b   Zhu, Jia Bin ^b   Ding, Bang He ^b   Liu, Xiao Ning ^b   Chen, Bao An ^a  

^a AFFILIATED ZHONGDA HOSPITAL OF SOUTHEAST UNIVERSITY   (China)

^b THE AFFILIATED HUAIAN NO 1 PEOPLE S HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Chronic myelogenous leukaemia; Homoharringtonine; Long term efficacy

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; HOMOHARRINGTONINE; HYDROXYUREA; MESSENGER RNA;

ADULT; AGED; ARTHRALGIA; ARTICLE; BLEEDING; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMPARATIVE STUDY; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; DISEASE DURATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GRANULOCYTOPENIA; HEMATOLOGICAL PARAMETERS; HUMAN; INFECTION; LIVER DISEASE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALAISE; MALE; MONOTHERAPY; NAUSEA; PANCYTOPENIA; RASH; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SALVAGE THERAPY; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING; WEAKNESS;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; FEMALE; FUSION PROTEINS, BCR-ABL; HARRINGTONINES; HUMANS; INTERFERON-ALPHA; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 68249138140     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2009.12.011     Document Type: Article

References (16)

1. Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999; 340: 1330-1340.
2. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-1037.
3. Kantarjian HM, Giles F, Quintás Cardama A, Cortes J. Important therapeutic targets in chronic myelogenous leukemia. Clin Cancer Res 2007; 13: 1089-1097.
4. Feldman E, Arlin Z, Ahmed T, Mittelman A, Puccio C, Chun H, et al. Homoharringtonine in combination with cytarabine for patients with acute myelogenous leukemia. Leukemia 1992; 6: 1189-1191.
5. O'Brien S, Kantarjian H, Koller C, Feldman E, Beran M, Andreeff M, et al. Sequential homoharringtonine and interferon-α in the treatment of early chronic phase chronic myelogenous leukemia. Blood 1999; 93: 4149-4153.
6. O'Brien S, Kantarjian H, Keating M, Beran M, Koller C, Robertson LE, et al. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood 1995; 86: 3322-3326.
7. Quintás Cardama A, Cortes J. Homoharringtonine for the treatment of chronic myelogenous leukemia. Expert Opin Pharmacother 2008; 9: 1029-1037.
8. Quintás Cardama A, Kantarjian H, Garcia Manero G, O'Brien S, Faderl S, Estrov Z, et al. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer 2007; 109: 248-255.
9. Marin D, Kaeda JS, Andreasson C, Saunders SM, Bua M, Olavarria E, et al. Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib. Cancer 2005; 103: 1850-1855.
10. Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, et al. Prognostic discrimination in "good risk" chronic granulocytic leukemia. Blood 1984; 63: 789-799.
11. Guilhot F, Apperley J, Kim DW, Bullorsky EO, Baccarani M, Roboz GJ, et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib resistant or intolerant chronic myeloid leukemia in accelerated Phase. Blood 2007; 109: 4143-4150.
12. Lange T, Bumm T, Otto S, Al Ali HK, Kovacs I, Krug D, et al. Quantitative reverse transcription polymerasechain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapy. Haematologica 2004; 89: 49-57.
13. Hughe T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006; 108: 28-37.
14. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349: 1423-1432.
15. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European Leukemia Net. Blood 2006; 108: 1809-1820.
16. Wang XQ, Chen ZX, Chen SC, Lin GW, Ji MR, Liang JY, et al. Prognostic analysis of refractory anaemia in adult myelodysplastic syndromes. Chin Med J 2009; 122: 643-647.